|
Q4 FY2022
As of Jul 31, 2022
|
Q4 FY2021
As of Jul 31, 2021
|
Q4 FY2020
As of Jul 31, 2020
|
|
|---|---|---|---|
| Assets | |||
| Current assets | |||
| Cash and cash equivalents | |||
| Restricted funds | |||
| Short-term investments | |||
| Cash held in escrow | |||
| Trade receivables | |||
| Commodity taxes recoverable and other receivables | |||
| Convertible debentures receivable | |||
| Prepaid expenses | |||
| Inventory | |||
| Biological assets | |||
| Assets held for sale | |||
| Total current assets | |||
| Non-current assets | |||
| Property, plant and equipment | |||
| Intangible assets | |||
| Investment in associate and joint ventures | |||
| Lease receivable | |||
| License and prepaid royalty | |||
| Long-term investments | |||
| Prepaid expenses | |||
| Goodwill | |||
| Total assets | |||
| Liabilities | |||
| Current liabilities | |||
| Accounts payable and accrued liabilities | |||
| Excise taxes payable | |||
| Warrant liabilities | |||
| Lease liability | |||
| Term loan | |||
| Loans and borrowings- current | |||
| Senior notes payable | |||
| Convertible debentures - current | |||
| Senior secured convertible note | |||
| Onerous contracts | |||
| Total current liabilities | |||
| Non-current liabilities | |||
| Lease liability | |||
| Convertible debentures | |||
| Deferred income tax liability | |||
| Other long-term liabilities | |||
| Total liabilities | |||
| Shareholders' equity | |||
| Share capital | |||
| Share-based payment reserve | |||
| Warrant reserve | |||
| Contributed surplus | |||
| Accumulated deficit | |||
| Accumulated other comprehensive income | |||
| Total equity attributable to shareholders of Hexo Corp. | |||
| Non-controlling interest | |||
| Total shareholders' equity | |||
| Total liabilities and shareholders' equity |
Loading...
